Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the objective response rate and 6-month
progression-free survival rate of XL184 in subjects with recurrent or progressive
glioblastoma multiforme. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET,
kinases implicated in tumor formation, growth and migration.